4s3 Bioscience, Inc. (4s3), a Boston-area biotherapeutics company focused on developing genetic disease therapies for orphan neuromuscular disorders, has closed a $20m Series A financing with KLP Enterprises, LLC.
The company intends to use the capital for continued development of a proprietary antibody technology that provides targeted and active intracellular delivery of active proteins, enzymes and other macromolecules to skeletal muscle.
This technology allows for the replacement of deficient proteins to skeletal muscle. It could have applications for the treatment of the underlying causes of muscular dystrophies, myopathies, motor neuron diseases, disease of the neuromuscular junction and various enzyme deficiency disorders.
KLP’s subsidiary, Alopexx Enterprises, LLC, will work with 4s3 to build and manage the company.
Founded in 2007 by Vice President of Research, Dustin Armstrong, Ph.D. and President and CEO, Timothy Harris, 4s3 Bioscience received seed funding from Genzyme Ventures in 2008.